Fuck Alzheimer's

We evaluated whether incident mild cognitive impairment (MCI) subtypes could be empirically derived in the Mayo Clinic Study of Aging. Read & Research Alzheimer’s More

A brain study in rats that explored different environments reveals that the anterior cingulate cortex drives the hippocampus in long-term memory recall. Read & Research Alzheimer’s More

New research finds that some Alzheimer’s-related biomarkers in the brain change as early as 34 years before the onset of visible symptoms. Read & Research Alzheimer’s More

The longitudinal trajectories of functional brain dynamics and the impact of genetic risk factors in individuals at risk for Alzheimer’s disease are poorly understood. Read & Research Alzheimer’s More

Blood-based biomarkers of pathophysiological brain amyloid β (Aβ) accumulation, particularly for preclinical target and large-scale interventions, are warranted to effectively enrich Alzheimer’s disease clinical trials and management. Read & Research Alzheimer’s More

The WHO have recently released a new set of guidelines around strategies for dementia prevention, in which they evaluate potential interventions. Read & Research Alzheimer’s More

According to a recent study, virtual reality might provide a useful tool for treating dementia. Among other things, it may help improve memory. Read & Research Alzheimer’s More

A drug that tackles toxic protein buildup in Alzheimer’s disease in a novel way has passed phase 1 of clinical trials, which tests safety in humans. Read & Research Alzheimer’s More

Identifying clinical measures that track disease in the earliest stages of frontotemporal lobar degeneration (FTLD) is important for clinical trials. Familial FTLD provides a unique paradigm to study early FTLD. Executive dysfunction is a clinically relevant hallmark of FTLD and may be a marker of disease progression. Read & Research Alzheimer’s More

18F-florbetaben is currently approved for the visual rule out of β-amyloid (Aβ) pathology. It is also used for recruitment and as an outcome measure in therapeutic trials, requiring accurate and reproducible quantification of Aβ burden in the brain. Read & Research Alzheimer’s More

A critical and as-yet unmet need in Alzheimer’s disease (AD) is the discovery of peripheral small molecule biomarkers. Given that brain pathology precedes clinical symptom onset, we set out to test whether metabolites in blood associated with pathology as indexed by cerebrospinal fluid (CSF) AD biomarkers. Read & Research Alzheimer’s More

A study uncovers the neuron and immune cell changes that explain why light therapy can reduce toxic brain proteins in mouse models of Alzheimer’s disease. Read & Research Alzheimer’s More

In most, if not all health systems, dementia is underdiagnosed, and when diagnosis occurs, it is typically at a relatively late stage in the disease process despite mounting evidence showing that a timely diagnosis would result in numerous benefits for patients, families, and society. Moving toward earlier diagnoses in Alzheimer’s Read & Research Alzheimer’s More

According to a new study, a cell phone game called ‘Sea Hero Quest’ could assist researchers in identifying people who are more at risk of Alzheimer’s. Read & Research Alzheimer’s More

In the article “Kallikrein-8 inhibition attenuates Alzheimer’s disease pathology in mice,” published in the December 2016 issue of Alzheimer’s & Dementia, the authors would like to amend the Acknowledgments section to include the contributions of Constanze Roggendorf, Anthony Stang, and Ilkay Yavuz. Read & Research Alzheimer’s More

Primary age-related tauopathy (PART) is characterized by the presence of neurofibrillary tangles and absent-minimal β-amyloid deposition. Transactive response DNA-binding protein of 43 kDa (TDP-43), a third protein, has recently garnished a lot of attention in Alzheimer’s disease where it is associated with memory loss and amygdala and hippocampal atrophy. We aimed Read & Research Alzheimer’s More

Low serum urate (sU) has been suggested to increase the risk of dementia since a reduction might impair antioxidant capacity. On the other hand, high sU is associated with increased cardiovascular risk which might increase the risk of dementia, especially for vascular dementia. Read & Research Alzheimer’s More

Experts have defined an under-recognized, newly named condition that mimics Alzheimer’s disease and propose guidelines for diagnosing and researching it. Read & Research Alzheimer’s More

Multidomain interventions, targeting multiple risk factors simultaneously, could be effective dementia prevention strategies, but may be burdensome and not universally acceptable. Read & Research Alzheimer’s More

Plasma biomarkers for Alzheimer’s disease (AD) diagnosis/stratification are a “Holy Grail” of AD research and intensively sought; however, there are no well-established plasma markers. Read & Research Alzheimer’s More

Data from up to 11 years of blood samples confirm neurofilament light protein as a potential noninvasive marker of Alzheimer’s disease progression. Read & Research Alzheimer’s More

We read with great interest the article by Stites et al. [1] and commend the authors for analyzing stigma of dementia among 317 adults from the US general public. Their study showed that 55% respondents expected a person with dementia to be discriminated by his/her employers, and approximately 46% respondents expected Read & Research Alzheimer’s More

Cerebral small vessel disease (cSVD) comprises pathological processes of the small vessels in the brain that may manifest clinically as stroke, cognitive impairment, dementia, or gait disturbance. It is generally accepted that endothelial dysfunction, including blood-brain barrier (BBB) failure, is pivotal in the pathophysiology. Recent years have seen increasing use Read & Research Alzheimer’s More

At blood levels that are typical in humans, an approved high blood pressure drug was able to clear toxic proteins of Parkinson’s disease from mouse brains. Read & Research Alzheimer’s More

Unlike for glucose, uptake of the brain’s main alternative fuel, ketones, remains normal in mild cognitive impairment (MCI). Ketogenic medium chain triglycerides (kMCTs) could improve cognition in MCI by providing the brain with more fuel. Read & Research Alzheimer’s More

Aaron Klug, who died on November 20, 2018, was a giant of molecular biology [1–3]. He was also a major figure in the study of dementia, especially Alzheimer’s disease. In 1982, Aaron was the sole recipient of the Nobel Prize in Chemistry “for his development of crystallographic electron microscopy and Read & Research Alzheimer’s More

Scientists have designed a protein that folds into alpha sheets that can block toxic beta-amyloid in brain cells before it forms into large clumps. Read & Research Alzheimer’s More

Redressing the rising threat of dementia demands not only an increase, but a diversification of efforts. We need new approaches, trials, and partners. We cannot afford to continue to only round up the usual suspects, β amyloid, and tau and try to stop them with a single drug “silver bullet”. Read & Research Alzheimer’s More

In the abstract “Validation of a simple severity scale for assessing ARIA-E,” published in the July 2017 Supplement issue of Alzheimer’s & Dementia, the values in the first column of Table 1 were incorrectly listed as “mm” instead of “cm.” The corrected table is below. Read & Research Alzheimer’s More

Working memory tends to decline with age, and this problem is characterized by poor synchronicity between brain regions. Can researchers ‘fix’ this issue? Read & Research Alzheimer’s More